Severe Skin Reaction in a Patient with Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate

Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a well-recognized, dose-related side-effect of imatinib mesylate, has been reported in 18 to 69% of patients with...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-11, Vol.26 (6C), p.4771-4774
Main Authors: FERRARESI, Virginia, CATRICALA, Caterina, CICCARESE, Mariangela, FERRARI, Angela, ZEULI, Massimo, COGNETTI, Francesco
Format: Article
Language:English
Subjects:
Benzamides
Biological and medical sciences
Erythema - chemically induced
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Stromal Tumors - drug therapy
Humans
Imatinib Mesylate
Medical sciences
Middle Aged
Piperazines - adverse effects
Piperazines - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a well-recognized, dose-related side-effect of imatinib mesylate, has been reported in 18 to 69% of patients with GIST treated with doses ranging from 400 to 800 mg once a day. In this case-report a severe skin reaction observed in a patient with GIST treated with imatinib mesylate, in an adjuvant setting and whose severity led to definitive drug discontinuation, is described. Therapeutic management and clinical course are illustrated.
ISSN:0250-7005
1791-7530